Status:
NO_LONGER_AVAILABLE
Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements
Lead Sponsor:
Joseph Jankovic
Conditions:
Hyperkinetic Movement Disorders
Eligibility:
All Genders
Brief Summary
Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The dru...
Detailed Description
The purpose of the protocol is to provide compassionate use of an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).
Eligibility Criteria
Inclusion
- Subjects evaluated here at Baylor in the PDCMDC demonstrating need for tetrabenazine treatment.
- Willing to sign informed consent.
- Willing to comply with procedures required as part of this study.
Exclusion
- Those subjects unwilling to comply with study requirements.
- Subjects unable to give informed consent.
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00642057
Last Update
March 24 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.